VTE Risk Remains High in Newly Diagnosed Multiple Myeloma Despite Thromboprophylaxis
Immunomodulatory imide drug (IMiD) therapy, including thalidomide and lenalidomide, has been associated with a high risk of VTE in patients with NDMM.
Multiple Myeloma
Elotuzumab, Lenalidomide-Dexamethasone Combo Improved OS in RRMM
The triplet regimen resulted in an 18% reduction in risk for death.
Daratumumab for Multiple Myeloma With High-Risk Cytogenetic Factors
The inclusion of daratumumab in multiple myeloma regimens may be linked to better progression-free survival.
Low Enrollment and Reporting of Racial Minorities in Multiple Myeloma Trials
Multiple myeloma trials appear to underrepresent racial minorities in enrollment and in reporting, with no obvious improvement in recent years.
Analysis of Carfilzomib vs Bortezomib Triplet Therapy for Newly Diagnosed Multiple Myeloma
The superiority of carfilzomib vs bortezomib in triplet therapy was compared in newly diagnosed multiple myeloma ineligible for immediate transplantation.
BCMA-Directed CAR T-Cell Therapy Gets Priority Review for Multiple Myeloma
The BLA is supported by data from the open-label, single-arm phase 2 KarMMa study.
Rapid Third-Infusion Protocol of Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma
An observational study determined that 90-minute rapid infusions of daratumumab for RRMM was safe and well-tolerated.
Multiple Myeloma: More Real-World Data Needed To Confirm Effectiveness of New Treatments
More data is needed to determine whether newer treatments are truly improving outcomes among patients with r/r multiple myeloma.
Outcomes After Daratumumab Addition to Induction Therapy in Newly Diagnosed Multiple Myeloma
Researchers assessed the effects of adding daratumumab to standard frontline induction therapy to treat MM in newly diagnosed, transplant-eligible patients.
Phase 1 Trial Featuring First shRNA-Edited CAR-T Therapy to Begin
FDA approves allogenic CAR T cells targeted at BCMA for phase 1 trial in relapsed/refractory multiple myeloma.
-
Loading...
-
Loading...
Next post in Myeloma
